The U.S. Food and Drug Administration recently issued an emergency use of Pfizer’s Paxlovid and Merck’s molnupiravir to treat COVID-19.
On Monday’s edition of “Closer Look” Dr. Zanthia Wiley, an Emory University infectious disease expert, discussed the science behind new antiviral drugs.
“These pills are not for prevention, they are specifically for people who are diagnosed with COVID who have early symptoms, we are talking about within five days you have symptoms and it’s for people who are at a higher risk of developing severe COVID,” Wiley said.
Wiley also discussed solutions to combating vaccine hesitancy and vaccine equity.
To listen to the full conversation, click the audio player above.
